Nunes Anne 4
4 · Anika Therapeutics, Inc. · Filed Mar 13, 2025
Insider Transaction Report
Form 4
Nunes Anne
SVP, Chief Operations Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-11+2,561→ 18,837 total - Tax Payment
Common Stock
2025-03-11$16.79/sh−752$12,626→ 18,085 total - Exercise/Conversion
Restricted Stock Unit
2025-03-11−2,561→ 0 totalExercise: $0.00→ Common Stock (2,561 underlying)
Footnotes (4)
- [F1]Reflects the third and final vesting installment of RSUs granted on March 11, 2022.
- [F2]Reflects an aggregate of 752 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2025.
- [F3]Reflects the closing price of ANIK common stock on March 11, 2025, the trading day to which the vesting of RSUs gave rise to tax withholding obligations.
- [F4]Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023.